Skip to main content
IDEAYA Biosciences, Inc. logo

IDEAYA Biosciences, Inc. — Investor Relations & Filings

Ticker · IDYA ISIN · US45166A1025 LEI · 549300ULW08F62IJML11 US Manufacturing
Open in API
Filings indexed 466 across all filing types
Latest filing 2019-10-11 Director's Dealing
Country US United States of America
Listing US IDYA

About IDEAYA Biosciences, Inc.

https://www.ideayabio.com/

IDEAYA Biosciences, Inc. is a clinical-stage precision medicine oncology company focused on the discovery, development, and commercialization of targeted therapeutics for cancer. The company's primary scientific approach is synthetic lethality, an emerging class of precision medicine that targets cancer cells based on specific genetic alterations. IDEAYA develops potential first-in-class and best-in-class therapies for patient populations selected using molecular diagnostics. Its integrated platform combines capabilities in target and biomarker discovery with the development of small molecule and protein degrader therapeutics to address unmet needs in cancer treatment.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2019-10-11 English
FORM 3
Director's Dealing
2019-10-11 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 30, 2019, by IDEAYA Biosciences, Inc. It reports the entry into a material definitive agreement (a lease amendment) and the termination of another lease. The content focuses on corporate real estate lease agreements and related operational changes. There are no financial statements, earnings data, or detailed financial analysis present. The document is a regulatory announcement of corporate events rather than a full financial report or earnings release. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories.
2019-10-05 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 12, 2019, for IDEAYA Biosciences, Inc. It announces the company's financial results for the second quarter ended June 30, 2019, and includes a press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2). The text explicitly states that the press release is furnished and not filed, and the presentation is attached as an exhibit. The document itself is a current report announcing financial results and providing an investor presentation, typical of an earnings release and investor presentation. Given the length (4212 characters) and content, it is not the full quarterly report but an announcement of results and presentation. Therefore, the best classification is Earnings Release (ER) because it announces quarterly financial results, and also includes an investor presentation (IP). However, since the main body focuses on the earnings announcement and the presentation is an exhibit, the primary classification is ER with high confidence.
2019-08-12 English
10-Q
Interim / Quarterly Report Q2 2019
2019-08-12 English
FORM 4
Director's Dealing
2019-08-01 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.